WASHINGTON & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung ...

CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable benefits ...

LONDON, United Kingdom — An endobronchial valve placed in the lung of a patient with homogeneous emphysema can lead to clinically meaningful improvements in lung function, exercise tolerance, and ...

The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the ...

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced that key long ...

Pulmonx has some additional ammunition in its bid to get its severe emphysema treatment valve FDA approval. The Redwood City, CA-based company released positive one-year-results from the LIBERATE ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe emphysema who received an endobronchial valve had sustained improvements in lung function ...

The US Food and Drug Administration (FDA) has approved the Zephyr Endobronchial Valve (Pulmonx Corp) to treat breathing difficulty associated with severe emphysema. "Treatment options are limited for ...

This section describes efficacy outcomes from the published literature that the committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see ...

Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial ...